No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 31 of the 32 quarters in the window, leaving 1 comparable quarter; at least 28 are needed.
Valuation vs own 10Y history: P/S 5.6x · 10Y median 282981.4x · 22nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 33
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:01:28.775Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Ensysce Biosciences, Inc. (ENSC) stock was $0.43 as of Oct 6, 2026, 10:00 AM EDT, up 2.00% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -83.4% · 3-year avg -70.6%/yr · 5-year avg -86.2%/yr
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.
Biotechnology · La Jolla, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.19
Revenue Est.
$1.20M
Last Quarter Results
EPS
$-0.20
vs Estimate
$-0.50
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ENSC | $6.57M | $0.43 | +2.00% | -83.36% | -86.22% | N/A | N/A |
| 2ENVB | $6.57M | $1.47 | -2.83% | N/A | N/A | N/A | vs ENSC |
| 3ACON | $6.80M | $2.36 | +0.77% | -68.01% | N/A | N/A | vs ENSC |
| 4BMRA | $6.34M | $2.05 | N/A | -26.68% | -46.66% | -20.93% | vs ENSC |
| 5BOLT | $6.82M | $3.55 | +1.43% | -33.96% | -57.61% | N/A | vs ENSC |
| 6FEMY | $6.28M | $2.08 | +2.97% | -83.83% | -57.27% | N/A | vs ENSC |
forward FY estimate
N/A
$1.20M
vs Estimate
$1.20M
Consensus Rating
Based on 1 analyst
Average Price Target
$8.25
+1830.3% upside
Low
$8.25
Current
$0.43
High
$8.25
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Quarter ending Dec 2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.09 | $-1.09 | $-1.09 | 1 |
| FY 2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.20M | $1.20M | $1.20M | 1 |
| Quarter ending Dec 2026 | $1.20M | $1.20M | $1.20M | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $4.60M | $4.60M | $4.60M | 1 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $2.50M |
| $2.50M |
| $2.50M |
| 1 |
